“It’s an extremely useful tool,” says Jonathan D. Tward, MD, PhD, of the Prolaris test.
“I think that getting a really personalized risk estimator can give you a better handle on how much you need to do to achieve the best outcome,” says Jonathan D. Tward, MD, PhD, in discussing the Prolaris test and how his use of the test has evolved over time. Tward is a professor of radiation oncology at the University of Utah, Salt Lake City.
Enzalutamide granted approval in EU for nmHSPC
April 24th 2024The approval is supported by data from the phase 3 EMBARK trial, which demonstrated that enzalutamide with or without leuprolide prolonged metastasis-free survival compared with leuprolide alone in patients with high-risk biochemically recurrent nmHSPC.